Elevation Oncology (ELEV)
(Delayed Data from NSDQ)
$0.78 USD
+0.02 (2.34%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.77 -0.01 (-1.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Income Statements
Fiscal Year end for Elevation Oncology, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 45 | 95 | 32 | 17 | 0 |
Income After Depreciation & Amortization | -45 | -95 | -32 | -17 | 0 |
Non-Operating Income | 0 | -1 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -46 | -95 | -32 | -17 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -46 | -95 | -32 | -17 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -46 | -95 | -32 | -17 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -46 | -95 | -32 | -17 | 0 |
Depreciation & Amortization (Cash Flow) | -1 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -45 | -95 | -32 | -17 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 34.08 | 23.27 | 12.13 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.34 | -4.09 | -2.64 | NA | NA |
Diluted Net EPS (GAAP) | -1.34 | -4.09 | -2.64 | NA | NA |
Fiscal Year end for Elevation Oncology, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 10.96 | 9.87 | 7.95 | 10.92 | 9.84 |
Income After SG&A, R&D, and Dept/Amort Expenses | -10.96 | -9.87 | -7.95 | -10.92 | -9.84 |
Non-Operating Income | 0.51 | -0.83 | 0.06 | 0.30 | -0.27 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -10.45 | -10.70 | -7.89 | -10.63 | -10.11 |
Income Taxes | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -10.46 | -10.71 | -7.90 | -10.64 | -10.11 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -10.46 | -10.71 | -7.90 | -10.64 | -10.11 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 59.02 | 47.37 | 42.42 | 42.40 | 27.58 |
Diluted EPS Before Non-Recurring Items | -0.18 | -0.23 | -0.19 | -0.25 | -0.37 |
Diluted Net EPS (GAAP) | -0.18 | -0.23 | -0.19 | -0.25 | -0.37 |